Stephen Webster

Mr. Stephen W.
Webster is an Independent Director at Eloxx Pharmaceuticals, Inc., an Independent Director at Cullinan Therapeutics, Inc. and an Independent Director at NextCure, Inc. He is on the Board of Directors at Eloxx Pharmaceuticals, Inc., Imvax, Inc., Cullinan Therapeutics, Inc., NextCure, Inc., Nuron Biotech, Inc. and Spark Therapeutics UK Ltd. Mr. Webster was previously employed as an Independent Director by Nexoplex Bio, Inc., an Independent Director by Cullinan Oncology LLC, a Chairman by TCR2 Therapeutics, Inc., a Member-Supervisory Board by Nabriva Therapeutics GmbH, an Independent Director by Nabriva Therapeutics Plc, a Chief Financial & Accounting Officer by Spark Therapeutics, Inc., an Independent Director by Viking Therapeutics, Inc., a Chief Financial Officer & Senior Vice President by Optimer Pharmaceuticals LLC, an Independent Director by HearUSA, Inc., a Chief Financial Officer & Senior Vice President by Adolor Corp., a Managing Director-Investment Banking Division by Broadpoint Securities, Inc., a Managing Director-Healthcare Investment Banking by Broadpoint.Gleacher Securities, a President & Chief Executive Officer by Neuronyx, Inc., and a Director-Investment Banking Division by PaineWebber, Inc. He also served on the board at Triplet Therapeutics, Inc. and Life Sciences Pennsylvania.
He received his undergraduate degree from Dartmouth College and an MBA from The Wharton School of the University of Pennsylvania.